• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster.

作者信息

Wagenhäuser Isabell, Reusch Julia, Gabel Alexander, Krone Lukas B, Kurzai Oliver, Petri Nils, Krone Manuel

机构信息

Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.

Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, Germany.

出版信息

Clin Microbiol Infect. 2023 Apr;29(4):554-556. doi: 10.1016/j.cmi.2023.01.008. Epub 2023 Jan 16.

DOI:10.1016/j.cmi.2023.01.008
PMID:36657489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9841732/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec33/9841732/14941bdd4131/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec33/9841732/14941bdd4131/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec33/9841732/14941bdd4131/gr1_lrg.jpg

相似文献

1
Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster.二价BNT162b2 mRNA原始株/奥密克戎BA.4-5加强针接种：与单价新冠病毒加强针相比的不良反应及无法工作情况
Clin Microbiol Infect. 2023 Apr;29(4):554-556. doi: 10.1016/j.cmi.2023.01.008. Epub 2023 Jan 16.
2
Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.2022 年 8 月 31 日至 10 月 23 日，12 岁及以上人群中双价 COVID-19 mRNA 疫苗加强针的安全性监测-美国。
MMWR Morb Mortal Wkly Rep. 2022 Nov 4;71(44):1401-1406. doi: 10.15585/mmwr.mm7144a3.
3
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.免疫实践咨询委员会关于使用二价加强针 COVID-19 疫苗的临时建议-美国，2022 年 10 月。
MMWR Morb Mortal Wkly Rep. 2022 Nov 11;71(45):1436-1441. doi: 10.15585/mmwr.mm7145a2.
4
Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.辉瑞 - 生物科技二价（原始株和奥密克戎BA.4/BA.5）新冠疫苗加强针在美国的公共卫生影响和经济价值
J Med Econ. 2023 Jan-Dec;26(1):509-524. doi: 10.1080/13696998.2023.2193067.
5
Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.5-11 岁儿童接种二价 COVID-19 mRNA 疫苗加强针的安全性监测-美国，2023 年 10 月 12 日-1 月 1 日。
MMWR Morb Mortal Wkly Rep. 2023 Jan 13;72(2):39-43. doi: 10.15585/mmwr.mm7202a5.
6
Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.接种 BNT162b2 加强针后对 SARS-CoV-2 奥密克戎 BA.1 和 BA.2 的血清中和作用。
Emerg Infect Dis. 2022 Jun;28(6):1274-1275. doi: 10.3201/eid2806.220503. Epub 2022 Mar 31.
7
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.养老院居民接种二价 COVID-19 疫苗后对原始 SARS-CoV-2 株和奥密克戎 BA.1 和 BA.4/BA.5 变异株的 SARS-CoV-2 抗体反应 - 俄亥俄州和罗得岛，2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):100-106. doi: 10.15585/mmwr.mm7204a4.
8
Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.同源和异源加强免疫在 Ad26.COV2.S 初免个体中的体液和细胞免疫原性：突破性感染的比较。
Front Immunol. 2023 Mar 7;14:1131229. doi: 10.3389/fimmu.2023.1131229. eCollection 2023.
9
Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.疫苗加强针、疫苗类型以及混合免疫对合并症老年人中针对 SARS-CoV-2 原始株和奥密克戎变异株亚谱系 BA.2 和 BA.5 的体液和细胞免疫的影响：一项横断面研究。
EBioMedicine. 2023 Feb;88:104446. doi: 10.1016/j.ebiom.2023.104446. Epub 2023 Jan 25.
10
Comparative Effectiveness of BNT162b2 and mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Registries in Japan.BNT162b2 和 mRNA-1273 加强针在 BNT162b2 基础免疫后对奥密克戎变异株的有效性比较：一项使用日本大规模基于人群的登记处的回顾性队列研究。
Clin Infect Dis. 2023 Jan 6;76(1):18-24. doi: 10.1093/cid/ciac763.

引用本文的文献

1
Intersecting SARS-CoV-2 spike mutations and global vaccine efficacy against COVID-19.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白突变与全球新冠疫苗有效性的交叉分析
Front Immunol. 2025 Mar 7;16:1435873. doi: 10.3389/fimmu.2025.1435873. eCollection 2025.
2
The Global Burden of Absenteeism Related to COVID-19 Vaccine Side Effects Among Healthcare Workers: A Systematic Review and Meta-Analysis.医护人员中与新冠疫苗副作用相关的缺勤全球负担：一项系统评价与荟萃分析
Vaccines (Basel). 2024 Oct 19;12(10):1196. doi: 10.3390/vaccines12101196.
3
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults.

本文引用的文献

1
Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.BA.5二价mRNA疫苗加强针的免疫原性。
N Engl J Med. 2023 Feb 9;388(6):565-567. doi: 10.1056/NEJMc2213948. Epub 2023 Jan 11.
2
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination.COVID-19 疫苗与流感疫苗联合接种的免疫原性和安全性。
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.01390-2022. Print 2023 Jan.
3
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster.来自mRNA二价加强针的针对BA.2.75.2、BQ.1.1和XBB的中和作用。
二价（原始毒株/奥密克戎BA.4/BA.5）新冠疫苗在成人中的比较有效性
Vaccines (Basel). 2023 Nov 11;11(11):1711. doi: 10.3390/vaccines11111711.
4
De Novo ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis After COVID-19 mRNA Vaccination: A Case Report.COVID-19 mRNA 疫苗接种后新发的抗中性粒细胞胞浆抗体阴性寡免疫性新月体肾小球肾炎：一例报告。
J Korean Med Sci. 2023 Oct 23;38(41):e341. doi: 10.3346/jkms.2023.38.e341.
5
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial.一种改良型 COVID-19 mRNA 疫苗（SW-BIC-213）作为异源加强针在健康成年人中的安全性和免疫原性：一项开放标签、两中心和多臂随机、1 期临床试验。
EBioMedicine. 2023 May;91:104586. doi: 10.1016/j.ebiom.2023.104586. Epub 2023 Apr 24.
6
Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines.脂质纳米颗粒介导的mRNA疫苗递送的最新进展
Vaccines (Basel). 2023 Mar 14;11(3):658. doi: 10.3390/vaccines11030658.
7
Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population.新型冠状病毒肺炎疫苗在自身免疫性疾病患者、有心脏问题的患者及健康人群中的安全性
Pathogens. 2023 Feb 2;12(2):233. doi: 10.3390/pathogens12020233.
8
Immune Response and Molecular Mechanisms of Cardiovascular Adverse Effects of Spike Proteins from SARS-CoV-2 and mRNA Vaccines.新冠病毒刺突蛋白及mRNA疫苗心血管不良反应的免疫反应与分子机制
Biomedicines. 2023 Feb 3;11(2):451. doi: 10.3390/biomedicines11020451.
N Engl J Med. 2023 Jan 12;388(2):183-185. doi: 10.1056/NEJMc2214293. Epub 2022 Dec 21.
4
Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.奥密克戎或德尔塔变异株感染及重症的 COVID-19 疫苗有效性评估。
JAMA Netw Open. 2022 Sep 1;5(9):e2232760. doi: 10.1001/jamanetworkopen.2022.32760.
5
A Bivalent Omicron-Containing Booster Vaccine against Covid-19.二价含奥密克戎成分的新冠病毒加强疫苗。
N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16.
6
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.